For more information call (888) LUHS-888.
Patients must be 18 years of age or older and have the following:
measurable, histologically or cytologically confirmed, unresectable locally advanced or metastatic cutaneous melanoma (stage III c or M1a-c) N-Ras mutated. (If N-Ras mutational status is unknown at screening, it must be prospectively defined before inclusion. If N-Ras mutational status is already known before screening, it must be retrospectively confirmed after inclusion by the sponsor.); tumor lesions amenable to biopsy or available tumor tissue as archival samples; women of childbearing potential must have a negative blood pregnancy test at the screening visit .
To compare the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine.